DRUG Latest Press Releases

-- January 9, 2026 --

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering Globe Newswire 11:56 AM

-- January 7, 2026 --

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock Globe Newswire 9:33 PM

-- January 6, 2026 --

Bright Minds Biosciences Announces Launch of US$100 Million Public Offering Globe Newswire 4:00 PM

Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE) Globe Newswire 7:16 AM

-- January 5, 2026 --

Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026 Globe Newswire 4:30 PM

-- November 25, 2025 --

Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting Globe Newswire 4:30 PM

-- November 17, 2025 --

Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS) Globe Newswire 6:50 AM

-- November 6, 2025 --

Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH Globe Newswire 6:30 AM

-- October 30, 2025 --

Bright Minds Biosciences to Present at Upcoming Conferences Globe Newswire 6:30 PM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software